Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NPs/PAs, and other HCPs involved in the treatment and management of colorectal cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Define key biomarkers that guide personalized treatment decision-making in patients with metastatic colorectal cancer (mCRC), incorporating multidisciplinary team support
- Apply the latest data on current and emerging treatment options for mCRC, including targeted therapies (e.g., BRAF, HER2, KRAS), into clinical practice for optimal patient outcomes
- Identify strategies for monitoring and managing adverse effects of current and emerging therapies for mCRC to ensure treatment adherence and patient safety
John H. Strickler, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
Duke University
Durham, NC
Co-Leader, Duke Molecular Tumor Board
Associate Director Clinical Research -- GI
Duke Cancer Institute
Durham, NC
Disclosures: Consultant: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Cytovation, Daiichi Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson & Johnson, Leap, Merck, Natera, Pfizer, Quanta Therapeutics, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, Triumvira, Xilio; Research: AbbVie, Amgen, Apollo Therapeutics, Bayer, BeOne, Daiichi Sankyo, Eli Lilly, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/ Genentech.
Stacey A. Cohen, MD
Associate Professor, Division of Hematology/Oncology
University of Washington
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA
Disclosures: Consultant: AbbVie, Agenus, DoMore Diagnostics, Exact Sciences, Guardant, GSK, Incyte, Janssen, Merck, Pfizer, Roche; IDMC Member: GSK.
Aparna Parikh, MD
Associate Professor of Medicine
Harvard Medical School
Director, Global Cancer Care Program
Massachusetts General Hospital
Boston, MA
Disclosures: Advisor/Consultant: 3T Biosciences, Abbvie, Adroya, Amgen, Astra Zeneca, BMS, Caris, Careset, CVS, Delicate, Do More Diagnostics, Eli Lilly, Exact, Foundation Medicine, GSK, Guardant, Hookipa, Incyte, Kahr, Merck, Mirati, MPM Capital, Naterara, Parithera, Pfizer, Phesi, PMV, Regeneron, Scare, Science For America, Seagen, Sirtex, Summit Therapeutics, Takeda, Third Rock Ventures, Value Analytics Labs, Xilio, Zola; Chief Scientist: Reversing Early Recurrence; Fees: Up to Date; Research Funding (to institution): Bristol Myers Squibb, Daiichi Sankyo, Erasca, Genentech, Mirati, Parthenon, PMV Pharmaceuticals, Revolution Medicine, Syndax; Shareholder: Cadex, C2i Genomics, Khora, OneCell, Parithera, XGenomes; Travel Fees: Karkinos Healthcare.
Kanwal P.S. Raghav, MBBS, MD
Assistant Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory board: AstraZeneca, Daiichi Sankyo, Pfizer; Researching Funding: AstraZeneca, Daiichi Sankyo.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here